2562-68-7

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 20 carbon (C) atoms, 16 hydrogen (H) atoms, 2 nitrogen (N) atoms, and 2 oxygen (O) atoms.

Explanation

The compound is a derivative of the benzimidazole ring, which is a heterocyclic aromatic organic compound containing nitrogen.

Explanation

The compound has a benzimidazole ring, which is a type of heterocyclic aromatic compound with a fused six-membered benzene ring and a five-membered imidazole ring.

Explanation

The benzimidazole ring in 1H-Benzimidazole, 2-(3,4-dimethoxyphenyl)-1-phenyl- has two substituents attached to it a 3,4-dimethoxyphenyl group and a phenyl group.

Explanation

The compound is used in various research and industrial applications, including the development of pharmaceuticals, agrochemicals, and materials science.

Explanation

Due to its structural properties, the compound may have potential therapeutic uses, and it is currently the subject of ongoing scientific study and research.

Explanation

The material provided does not give information about the chemical stability of the compound. Further research would be needed to determine its stability under various conditions.

Explanation

The material provided does not mention the solubility of the compound in different solvents. Solubility can be an important factor in determining its applications and reactivity.

Explanation

The material provided does not provide information about the reactivity of the compound with other chemicals. Further research would be needed to understand its reactivity profile.

Explanation

The material provided does not discuss the toxicity of the compound. Further research would be needed to determine its potential hazards and safety precautions.

Structure

1H-Benzimidazole derivative

Heterocyclic Aromatic Compound

Contains a benzimidazole ring

Substituents

3,4-Dimethoxyphenyl and phenyl groups

Applications

Pharmaceutical, agrochemical, and materials science

Potential Therapeutic Uses

Ongoing scientific study and research

Chemical Stability

Unknown

Solubility

Unknown

Reactivity

Unknown

Toxicity

Unknown

Upstream product

• 68413-92-3 sodium (3,4-dimethoxyphenyl)(hydroxy)methanesulfonate 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 3535-37-3 3,4-dimethoxybenzoic acid chloride 

Downstream Products

• 1609033-47-7 C₈₄H₆₈Cl₂Ir₂N₈O₈ 

Relevant academic research and scientific papers

Tuning the photophysical and electrochemical properties of iridium(III) 2-aryl-1-phenylbenzimidazole complexes

A series of heteroleptic bis-cyclometalated iridium(III) complexes, [Ir(cpbi)2(H2dcbpy)][PF6] (1), [Ir(pbi) 2(H2dcbpy)][PF6] (2), and [Ir(mpbi) 2(H2dcbpy)][PF6] (3), where pbi = 1,2-diphenylbenzimidazole, cpbi = 2-(4-chlorophenyl)-1-phenylbenzimidazole, mpbi = 2-(3,4-dimethoxyphenyl)-1-phenylbenzimidazole, and H2dcbpy = 2,2′-bipyridine-4,4′-dicarboxylic acid has been synthesized and characterized by elemental analysis, 1H, 31P NMR, and high resolution mass-spectra. Molecular structure of complex 3 has been determined from single-crystal X-ray analysis. The complexes exhibit absorption up to 550 nm with molar absorptivities of 2500 M-1 cm-1. They have strong luminescence in broad yellow-to-red region in solutions at room temperature. While chloro-substituent (complex 1) causes a little hypsochromic shift of the absorption maxima compared to unsubstituted 2, introduction of two methoxy-groups (complex 3) gives rise to a bathochromic shift of about 100 nm. Alternating current voltammetry studies of the complexes indicates reversible oxidation and reduction potentials. Calculated excited state oxidation potentials for 1-3 are negative enough to efficiently inject electrons into the conduction band of TiO2 (EF). 2014 Elsevier B.V. All rights reserved.

Benzimidazoles: A new class of carbonic anhydrase inhibitors

Carbonic anhydrase inhibitory activity of benzimidazole derivatives 1-24 has been evaluated. Compounds 22 (IC50 = 7.47 ± 0.39 μM), 21 (IC50 = 10.31 ± 0.11 μM), 20 (IC50 = 23.1 ± 1.78 μM), 12 (IC50 = 12.16 ± 0.10

Synthesis and β-glucuronidase inhibitory potential of benzimidazole derivatives

Benzimidazole derivatives 1-24 have been synthesized and their in vitro β-glucuronidase inhibitory activitiy was evaluated. Compounds 15 (IC 50 = 6.33 ± 0.40 μM), 7 (IC50 = 22.0 ± 0.33 μM), 2 (IC50 = 23.1 ± 1.78 μM), 17 (I

Conventional and microwave-assisted synthesis of benzimidazole derivatives and their in vitro inhibition of human cyclooxygenase

A large series of 1,2-diaryl-benzimidazole and 2-aryl-1H-benzimidazole derivatives were synthesized with slight differences using both microwave irradiation and conventional heating methods. Usually higher yields and time reactions reduction were obtained

Methods of treating or preventing sleep apnea

This invention provides methods for the treatment or prevention of sleep apnea in a mammal which compris administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.

Methods of treating or preventing interstitial cystitis

PCT No. PCT/US97/03895 Sec. 371 Date Aug. 25, 1998 Sec. 102(e) Date Aug. 25, 1998 PCT Filed Mar. 7, 1997 PCT Pub. No. WO97/33873 PCT Pub. Date Sep. 18, 1997This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.

METHODS FOR TREATING A PHYSIOLOGICAL DISORDER ASSOCIATED WITH BETA-AMYLOID PEPTIDE

This invention provides substituted benzimidazoles which are useful in treating or preventing conditions associated with beta-amyloid peptide. Some such conditions associated with beta-amyloid peptide include Alzheimer's Disease, Down's Symdrome and amyloidosis of the Dutch type

Non-peptidyl tachykinin receptor antagonists

This invention provides novel substituted benzimidazoles of formula II which are useful as tachykinin receptor antagonists. This invention also provides methods for treating a condition associated with an excess of tachykinin which comprises administering to a mammal in need thereof one of a series of substituted benzimidazoles. This invention further provides pharmaceutical formulations comprising one or more of the substituted benzimidazoles of the present invention in association with pharmaceutical carriers, diluents, or excipients. A and Ra-Re are as defined in the description.